| Literature DB >> 36098965 |
Nadim Mahmud1,2,3,4, David S Goldberg5, Samir Abu-Gazala6, James D Lewis1,3,4, David E Kaplan1,2.
Abstract
Importance: Patients with cirrhosis have increased risk of postoperative mortality. Several models have been developed to estimate this risk; however, current risk estimation scores cannot compare surgical risk with the risk of not operating. Objective: To identify clinical optimal thresholds to favor operative or nonoperative management for a common cirrhosis surgical scenario, the symptomatic abdominal hernia. Design, Setting, and Participants: This was a Markov cohort decision analytical modeling study evaluating elective surgery vs nonoperative management for a symptomatic abdominal hernia in a patient with cirrhosis. Transition probabilities and utilities were derived from the literature and from data using an established cirrhosis cohort in the Veterans Health Administration. Participants included patients who were referred to a surgery clinic for a symptomatic abdominal hernia. Data were obtained from patients diagnosed with cirrhosis between January 1, 2008 and December 31, 2018. Data were analyzed from January 1 to May 1, 2022. Main Outcomes and Measures: Expected quality-adjusted life-years (QALYs) were estimated for each pathway and iterated over baseline model for end-stage liver disease-sodium (MELD-Na) scores ranging from 6 to 25. Markov models were cycled over a 5-year time horizon.Entities:
Mesh:
Year: 2022 PMID: 36098965 PMCID: PMC9471978 DOI: 10.1001/jamanetworkopen.2022.31601
Source DB: PubMed Journal: JAMA Netw Open ISSN: 2574-3805
Figure 1. Markov State Transition Diagram
Transition Probabilities and Utilities Used in Base Markov Decision Models
| State | Estimate, per cycle | Source |
|---|---|---|
| Transition probabilities | ||
| Symptomatic hernia to hernia incarceration | 0.071 | Marsman et al[ |
| Successful incarcerated hernia reduction | 0.333 | Marsman et al,[ |
| Symptomatic hernia to flood syndrome (ruptured hernia) | 0.008 | Marsman et al.[ |
| Resolved hernia to symptomatic hernia (hernia recurrence) | 0.01 | Ammar et al,[ |
| Probability of postoperative mortality, elective setting | pVPS_mortality | Mahmud et al[ |
| Probability of postoperative mortality, emergent setting | pVPS_eMortality | Mahmud et al[ |
| Probability of complicated postoperative recovery, elective setting | pVPS_comp | Mahmud et al[ |
| Probability of complicated postoperative recovery, emergent setting | pVPS_eComp | Mahmud et al[ |
| Probability of mortality attributable to baseline liver disease (ie, no surgery) | pMELDNa_mortality | Derived in the present study |
| Base state utilities | ||
| Resolved hernia (utility associated with cirrhosis alone, assume decompensated status) | 0.324 | Sherman et al,[ |
| Symptomatic hernia (90% of utility associated with resolved hernia) | 0.292 | Poobalan et al,[ |
| Transition state utilities (penalties) | ||
| Incarceration (22.8% decrease from best health state) | −0.148 | Bass et al,[ |
| Flood syndrome (42.9% decrease from best health state) | −0.278 | Bass et al,[ |
| Elective surgery (8.8% decrease from best health state) | −0.057 | Bass et al,[ |
| Emergent surgery (21.8% decrease from best health state) | −0.141 | Bass et al,[ |
| Complicated surgical recovery (20.8% decrease from best health state) | −0.134 | Bass et al,[ |
Abbreviations: MELD-NA, model for end-stage liver disease–sodium; p, probability; VPS, VOCAL-Penn Score.
Varies by current MELD-Na in the model cycle. Further information is provided in eTable 1 in the Supplement.
Characteristics of Abdominal Hernia Patients Who Did or Did Not Proceed to Surgical Treatment
| Characteristic | Received surgical treatment, No. (%) | ||
|---|---|---|---|
| No (N = 1752) | Yes (N = 988) | ||
| Age, median (IQR), y | 61 (56-67) | 62 (56-66) | .72 |
| Sex | |||
| Women | 26 (1.5) | 15 (1.5) | .94 |
| Men | 1726 (98.5) | 973 (98.5) | |
| Race and ethnicity | |||
| Asian | 17 (1.0) | 14 (1.4) | .69 |
| Black | 244 (13.9) | 139 (14.1) | |
| Hispanic | 135 (7.7) | 80 (8.1) | |
| White | 1205 (68.8) | 681 (68.9) | |
| Other | 151 (8.6) | 74 (7.5) | |
| Smoking | |||
| Never | 545 (31.6) | 276 (28.2) | .15 |
| Former | 615 (35.6) | 356 (36.3) | |
| Current | 566 (32.8) | 348 (35.5) | |
| Alcohol use disorder | 403 (23.0) | 210 (21.3) | .29 |
| BMI, median (IQR) | 27.4 (24.3-31.6) | 26.8 (23.7-30.5) | .001 |
| Etiology of liver disease | |||
| HCV | 242 (13.8) | 187 (18.9) | .003 |
| Hepatitis B virus | 14 (0.8) | 6 (0.6) | |
| Alcohol-related liver disease | 726 (41.5) | 401 (40.6) | |
| HCV and ALD | 422 (24.1) | 242 (24.5) | |
| Non-alcoholic fatty liver disease | 291 (16.6) | 129 (13.1) | |
| Other | 54 (3.1) | 22 (2.2) | |
| CTP class | |||
| A | 1072 (61.2) | 734 (74.3) | <.001 |
| B | 651 (37.2) | 241 (24.4) | |
| C | 29 (1.7) | 13 (1.3) | |
| MELD, median (IQR) | 9 (6-14) | 6 (6-9) | <.001 |
| MELD-Na, median (IQR) | 11 (7-16) | 9 (6-13) | <.001 |
| Decompensated cirrhosis | 1089 (62.2) | 533 (53.9) | <.001 |
| Ascites | 787 (44.9) | 411 (41.6) | .09 |
| Obesity | 561 (32.0) | 282 (28.5) | .06 |
| Diabetes | 946 (54.0) | 487 (49.3) | .02 |
| Coronary artery disease | 436 (24.9) | 203 (20.5) | .01 |
| Heart failure | 292 (16.7) | 130 (13.2) | .02 |
| Atrial fibrillation | 209 (11.9) | 101 (10.2) | .18 |
| CKD | 636 (38.3) | 299 (31.9) | .001 |
| COPD | 714 (43.0) | 407 (43.5) | .81 |
| Laboratory measurements, median (IQR) | |||
| Sodium, mEq/L | 138 (135-140) | 138 (136-140) | .007 |
| Creatinine, mg/dL | 0.9 (0.8-1.2) | 0.9 (0.8-1.1) | .43 |
| Albumin, g/dL | 3.3 (2.8-3.8) | 3.6 (3.1-4.1) | <.001 |
| Total bilirubin, mg/dL | 1.1 (0.7-1.9) | 0.9 (0.6-1.6) | <.001 |
| Platelet Count, ×103/µL | 121 (82-178) | 142 (100-194) | <.001 |
| INR | 1.2 (1.1-1.5) | 1.2 (1.1-1.3) | <.001 |
Abbreviations: ALD, alcohol-related liver disease; BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); CTP, Child-Turcotte-Pugh; HCV, hepatitis C virus; MELD, model for end-stage liver disease; INR, international normalized ratio; MELD-Na, model for end-stage liver disease–sodium.
SI conversion factors: To convert albumin to grams per liter, multiply by 10; bilirubin to micromoles per liter, multiply by 17.104; creatinine to micromoles per liter, multiply by 76.25; platelet count to ×109/L, multiply by 1.
Other race or ethnicity includes selection for American Indian, Alaska Native, other, or unknown or declined to answer.
Figure 2. Projected Risk of 180-Day Mortality with Operative and Nonoperative Strategies Expressed
MELD-Na indicates model for end-stage liver disease–sodium; VPS, VOCAL-Penn Score.
Figure 3. Results of Primary Markov Decision Analysis
MELD-Na indicates model for end-stage liver disease–sodium; QALY, quality-adjusted life-years.